神经生长因子对重型颅脑损伤患者的治疗效果及血清MMP-2、NSE影响研究

目的 探究神经生长因子对重型颅脑损伤患者的治疗效果及血清基质金属蛋白酶-2(MMP-2)、血清神经元特异性烯醇化酶(NSE)水平影响研究，以为重型颅脑损伤患者的治疗提供参考。 方法 分析2014年6月—2015年12月91例在温州市人民医院接受治疗的重症颅脑损伤患者的临床资料，对照组(44例)给予常规对症治疗，观察组(47例)在常规治疗基础上增加鼠神经生长因子进行治疗。比较2组患者治疗前后血清MMP-2、NSE水平、GCS评分及不良反应发生率的差异。 结果 观察组患者治疗14 d后血清中MMP-2、NSE水平明显低于治疗前水平，观察组治疗14 d后MMP-2明显高于对照组，观察组治疗14 d后NSE水平低于对照组，差异均具有统计学意义(P＜0.05)；2组患者治疗14 d后GCS评分明显高于治疗前，观察组患者治疗14 d后GCS评分显著高于对照组，差异均具有统计学意义(P＜0.05)；治疗2周后，观察组患者中出现恶心、呕吐3例，头晕2例，下肢疼痛2例，不良反应率14.89%，对照组中恶心、呕吐2例，头晕1例，心率失常1例，不良反应率9.09%，2组患者不良反应发生率比较，差异不具有统计学意义(χ2=0.720，P=0.396)。 结论 神经生长因子可明显降低血清中MMP-2、NSE水平，有助于患者神经功能的恢复，安全性较好。 

Curative effect of nerve growth factor on severe craniocerebral injury and its influence on the levels of MMP-2 and NSE

Objective To investigate the curative effect of nerve growth factor on severe craniocerebral injury and its influence on the levels of matrix metalloproteinase-2(MMP-2) and neuron-specific enolase(NSE),to provide reference for the treatment of patients with severe craniocerebral injury. Methods The clinical data of 91 cases of severe craniocerebral injury in our hospital between June,2014 and December,2015 was reviewed.The control group(44 cases) received conventional symptomatic treatment,while the observation group(47 cases) received additional nerve growth factor treatment on the basis of conventional treatment.The levels of serum NSE and MMP-2,GCS score and the incidence of adverse incidence before and after the treatment were compared between the two groups. Results The serum level of MMP-2 and NSE at 14 d after the treatment in observation group was significantly lower than that before the treatment,the level of MMP-2 at d 14 after the treatment in the observation group was obviously higher than that in the control group,while the level of NSE at 14 d after the treatment in the observation group was lower than that in the control group,the difference was all statistically significant(P<0.05);GCS score of 14 days after treatment in Two groups was significantly higher than before treatment,GCS score at 14 d after the treatment in the observation group was significantly greater than that in the control group,the difference was statistically significant(P<0.05);After two weeks of treatment,the incidence of adverse reaction in the observation group was 14.89% (nausea and vomiting in 3 cases,dizziness in 2 cases,and lower extremity pain in 2 cases) and in the control group was 9.09% (nausea and vomiting in 2 cases,dizziness in 1 cases,and arrhythmia in 1 cases),there were no statistically significant difference(χ2=0.720,P=0.396). Conclusion The nerve growth factor can obviously reduce the serum level of MMP-2 and NSE,and contribute to the recovery of neural function with a good security.